Lexicon Pharmaceuticals, Inc.
LXRX
$1.88
$0.000.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 21.10M | 5.49M | 14.18M | 28.87M | 1.26M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.10M | 5.49M | 14.18M | 28.87M | 1.26M |
| Cost of Revenue | 12.86M | -43.32M | 18.77M | 1.65M | 15.33M |
| Gross Profit | 8.24M | 48.81M | -4.59M | 27.21M | -14.07M |
| SG&A Expenses | 9.23M | 8.76M | 7.60M | 9.35M | 11.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.10M | 20.27M | 26.37M | 25.13M | 26.94M |
| Operating Income | -996.00K | -14.78M | -12.19M | 3.74M | -25.68M |
| Income Before Tax | -1.04M | -15.53M | -12.77M | 3.25M | -25.30M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.04M | -15.53M | -12.77M | 3.25M | -25.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.04M | -15.53M | -12.77M | 3.25M | -25.30M |
| EBIT | -996.00K | -14.78M | -12.19M | 3.74M | -25.68M |
| EBITDA | -886.00K | -14.66M | -12.04M | 3.91M | -25.50M |
| EPS Basic | 0.00 | -0.04 | -0.04 | 0.01 | -0.07 |
| Normalized Basic EPS | 0.00 | -0.03 | -0.02 | 0.01 | -0.04 |
| EPS Diluted | 0.00 | -0.04 | -0.04 | 0.01 | -0.07 |
| Normalized Diluted EPS | 0.00 | -0.03 | -0.02 | 0.01 | -0.04 |
| Average Basic Shares Outstanding | 400.24M | 363.43M | 363.40M | 363.29M | 362.07M |
| Average Diluted Shares Outstanding | 400.24M | 363.43M | 363.40M | 363.57M | 362.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |